Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Efavirenz Teva

Efavirenz Teva 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 16

HOS-215304 · Präparat HOS-155418

Efavirenz: AUC: ↔ Cmax: ↑ 11% (↑ 6 to ↑ 16) Cmin: ↔ (CYP3A4 induction) Paroxetine/efavirenz No clinically significant No dose adjustment is necessary (20 mg once daily/600 mg once pharmacokinetic interaction for either medicinal product. daily) Fluoxetine/efavirenz Interaction not studied. Since No dose adjustment is necessary fluoxetine shares a similar metabolic for either medicinal product. profile with paroxetine, i.e. a strong CYP2D6 inhibitory effect, a similar lack of interaction would be expected for fluoxetine. Norepinephrine and dopamine reuptake inhibitor Bupropion/efavirenz Bupropion: Increases in bupropion dosage [150 mg single dose (sustained AUC: ↓ 55% (↓ 48 to ↓ 62) should be guided by clinical release)/600 mg once daily] Cmax: ↓ 34% (↓ 21 to ↓ 47) response, but the maximum recommended dose of bupropion Hydroxybupropion: should not be exceeded. No dose AUC: ↔ adjustment is necessary for Cmax: ↑ 50% (↑ 20 to ↑ 80) efavirenz. (CYP2B6 induction) ANTIHISTAMINES Cetirizine/efavirenz Cetirizine: No dose adjustment is necessary (10 mg single dose/600 mg once AUC: ↔ for either medicinal product. daily) Cmax: ↓ 24% (↓ 18 to ↓ 30) These changes are not considered clinically significant.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) norepinephrine (HOS-090547) bupropion (HOS-086329) dopamine (HOS-085948) fluoxetine (HOS-085946) cetirizine (HOS-215305)